Haroon Khalid, MD
Allergy & Immunology · Kansas City, MONPI 1326200767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 32.4% of the total.
Across 338 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$477
- Sanofi$405
- Genentech USA, Inc.$366
- Optinose US, Inc.$318
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$6,36898%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $2,111 |
| GSK | 55 | $1,031 |
| Regeneron Healthcare Solutions, Inc. | 31 | $477 |
| Sanofi | 21 | $405 |
| Genentech USA, Inc. | 23 | $366 |
| Optinose US, Inc. | 16 | $318 |
| Boehringer Ingelheim | 17 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $186 |
| Amgen | 8 | $183 |
| Novartis | 8 | $173 |
| Kaleo, Inc. | 10 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $116 |
| Teva Pharmaceuticals USA, Inc. | 7 | $111 |
| Pfizer | 4 | $96 |
| CSL Behring | 4 | $87 |
| Incyte Corporation | 3 | $75 |
| Alk-abello, Inc | 3 | $47 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $43 |
| LEO Pharma Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $29 |
| Hospira, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| GC Biopharma USA, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $17 |
| Merck | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| USWM, LLC | 1 | $13 |
How this compares
$6,511 in reported general payments places this provider in the 65th percentile of 61 allergy & immunology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $54,678 |
| Dupixent SyringeDupilumab | 13 | $48,356 |
| XolairOmalizumab | 22 | $46,402 |
| Arnuity ElliptaFluticasone Furoate | 34 | $10,282 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,884 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $7,847 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,350 |
| Epinephrine | 14 | $2,304 |
| Azelastine Hcl | 54 | $2,148 |
| Montelukast Sodium | 163 | $1,342 |
| Asmanex HfaMometasone Furoate | 11 | $1,202 |
| Ipratropium Bromide | 37 | $1,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $633 |
| Levocetirizine Dihydrochloride | 47 | $453 |
| Fluticasone Propionate | 15 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $1,031 | $74,843115 claims |
| AstraZenecaSymbicort | $2,111 | $7,35028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 61 allergy & immunology providers in Missouri.
Other allergy & immunology in Kansas City
- Lanny RosenwasserKansas City$46K
- Bridgette JonesKansas City$13K
- Travis SifersKansas City$3K
- Aarti PandyaKansas City$3K
- Neha PatelKansas City$1K
- Maggie BarnthouseKansas City$633
- Maya NandaKansas City$551
- Manali ShahKansas City$327
- Salman AljubranKansas City$125
- Zachary JacobsKansas City$33
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.